Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2018 1
2021 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean urol rivera mg (1 results)?
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. J Am Soc Nephrol. 2024 Oct 25. doi: 10.1681/ASN.0000000534. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39455063 No abstract available.
Risk factors of death or chronic renal replacement therapy requirements in patients with thrombotic microangiopathies without ADAMTS-13 deficiency.
Uriol-Rivera MG, Andrade BL, Bonet AM, Mulet AO, Ruiz CB, Parraga LP, Lumbreras J, Rota JIA, Servalos MF, Balaguer JF, Ferreres LP, Valles MJP, Valero RMRG, Sanchez ST, Martin AG, Garcia JR, Cobo CG, Ramis-Cabrer D; Son Espases Multidisciplinary Team for the management of Thrombotic Microangiopathy. Uriol-Rivera MG, et al. Eur J Haematol. 2024 Oct;113(4):510-520. doi: 10.1111/ejh.14261. Epub 2024 Jul 2. Eur J Haematol. 2024. PMID: 38955806
Impact of a multidisciplinary team for the management of thrombotic microangiopathy.
Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C, López Andrade B, Lumbreras J, Obrador Mulet A, Perez Montaña A, Ferreruela Serlavos M, Ayestarán Rota JI, Ferrer Balaguer J, Delgado Sanchez O, Pallares Ferreres L, Mas Bonet A, Picado Valles MJ, de Gopegui Valero RMR. Uriol Rivera MG, et al. PLoS One. 2018 Nov 2;13(11):e0206558. doi: 10.1371/journal.pone.0206558. eCollection 2018. PLoS One. 2018. PMID: 30388144 Free PMC article.
Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial.
Uriol-Rivera MG, Obrador-Mulet A, Jimenez-Mendoza S, Corral-Baez A, Perianez-Parraga L, Garcia-Alvarez A, de la Prada FJ. Uriol-Rivera MG, et al. J Hematol. 2021 Dec;10(6):255-265. doi: 10.14740/jh862. Epub 2021 Nov 29. J Hematol. 2021. PMID: 35059087 Free PMC article.
Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Luque-Ramírez M, et al. Among authors: uriol rivera mg. Hum Reprod. 2008 Jul;23(7):1594-601. doi: 10.1093/humrep/den095. Epub 2008 Mar 27. Hum Reprod. 2008. PMID: 18375410 Clinical Trial.
Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients.
Uriol-Rivera MG, Obrador-Mulet A, Juliá MR, Daza-Cajigal V, Delgado-Sanchez O, Garcia Alvarez A, Gomez-Lobon A, Carrillo-Garcia P, Saus-Sarrias C, Gómez-Cobo C, Ramis-Cabrer D, Gasco Company J, Molina-Infante J; Balear IgA Research and Treatment Project. Uriol-Rivera MG, et al. Sci Rep. 2024 Feb 28;14(1):4866. doi: 10.1038/s41598-024-55425-7. Sci Rep. 2024. PMID: 38418932 Free PMC article.